TY - JOUR
T1 - Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers
T2 - A longitudinal study spanning two decades
AU - Boele, Florien W.
AU - den Otter, Patricia W. M.
AU - Reijneveld, Jaap C.
AU - de Witt Hamer, Philip C.
AU - van Thuijl, Hinke F.
AU - Lorenz, Linda M. C.
AU - Wesseling, Pieter
AU - Lagerwaard, Frank J.
AU - Taphoorn, Martin J. B.
AU - Kouwenhoven, Mathilde C. M.
AU - Snijders, Tom J.
AU - Douw, Linda
AU - Klein, Martin
N1 - Funding Information: Funding. None. Publisher Copyright: © 2022 The Author(s). Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - BACKGROUND: While patients with diffuse low-grade glioma (LGG) often survive for years, there is a risk of tumor progression which may impact patients' long-term health-related quality of life (HRQOL) and neurocognitive functioning (NCF). We present a follow-up of LGG patients and their informal caregivers (T3) who took part in our previous HRQOL investigations (T1, M = 7 and T2 M = 13 years after diagnosis). METHODS: Participants completed HRQOL (short form-36 health survey [SF-36]; EORTC-BN20), fatigue (Checklist Individual Strength [CIS]), and depression (Center for Epidemiological Studies-Depression [CES-D]) questionnaires and underwent NCF assessments. T3 scores were compared with matched controls. Changes over time (T1-T2-T3) on group and participant level were assessed. Where available, histology of the initial tumor was revised and immunohistochemical staining for IDH1 R132H mutant protein was performed. RESULTS: Thirty patients and nineteen caregivers participated. Of N = 11 with tissue available, 3 patients had confirmed diffuse LGG. At T3, patients (M = 26 years after diagnosis) had HRQOL and NCF similar to, or better than controls, yet 23.3% and 53.3% scored above the cut-off for depression (≥16 CES-D) and fatigue (≥35 CIS), respectively. Caregivers' HRQOL was similar to controls but reported high rates of fatigue (63.2%). Over time, patients' mental health improved (P < .05). Minimal detectable change in HRQOL over time was observed in individual patients (30% improvement; 23.3% decline; 20% both improvement and decline) with 23.3% remaining stable. NCF remained stable or improved in 82.8% of patients. CONCLUSIONS: While HRQOL and NCF do not appear greatly impacted during long-term survivorship in LGG, depressive symptoms and fatigue are persistent.
AB - BACKGROUND: While patients with diffuse low-grade glioma (LGG) often survive for years, there is a risk of tumor progression which may impact patients' long-term health-related quality of life (HRQOL) and neurocognitive functioning (NCF). We present a follow-up of LGG patients and their informal caregivers (T3) who took part in our previous HRQOL investigations (T1, M = 7 and T2 M = 13 years after diagnosis). METHODS: Participants completed HRQOL (short form-36 health survey [SF-36]; EORTC-BN20), fatigue (Checklist Individual Strength [CIS]), and depression (Center for Epidemiological Studies-Depression [CES-D]) questionnaires and underwent NCF assessments. T3 scores were compared with matched controls. Changes over time (T1-T2-T3) on group and participant level were assessed. Where available, histology of the initial tumor was revised and immunohistochemical staining for IDH1 R132H mutant protein was performed. RESULTS: Thirty patients and nineteen caregivers participated. Of N = 11 with tissue available, 3 patients had confirmed diffuse LGG. At T3, patients (M = 26 years after diagnosis) had HRQOL and NCF similar to, or better than controls, yet 23.3% and 53.3% scored above the cut-off for depression (≥16 CES-D) and fatigue (≥35 CIS), respectively. Caregivers' HRQOL was similar to controls but reported high rates of fatigue (63.2%). Over time, patients' mental health improved (P < .05). Minimal detectable change in HRQOL over time was observed in individual patients (30% improvement; 23.3% decline; 20% both improvement and decline) with 23.3% remaining stable. NCF remained stable or improved in 82.8% of patients. CONCLUSIONS: While HRQOL and NCF do not appear greatly impacted during long-term survivorship in LGG, depressive symptoms and fatigue are persistent.
KW - depression
KW - fatigue
KW - low-grade glioma
KW - quality of life
KW - survivorship
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85144123776&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/35908832
U2 - https://doi.org/10.1093/neuonc/noac185
DO - https://doi.org/10.1093/neuonc/noac185
M3 - Article
C2 - 35908832
SN - 1522-8517
VL - 25
SP - 351
EP - 364
JO - Neuro-oncology
JF - Neuro-oncology
IS - 2
ER -